Published September 2017
| Version v1
Journal article
Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort
Contributors
Others:
- Simon Fraser University (SFU.ca)
- British Columbia
- Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD) ; Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA)
- Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)
- Hôpital Archet 2 [Nice] (CHU)
- Epidémiologie et Biostatistique [Bordeaux] ; Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Bordeaux population health (BPH) ; Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED) ; Université Bordeaux Segalen - Bordeaux 2
- Université Paris-Sud - Paris 11 (UP11)
- Antoine Beclere Hospital, Clamart
- Les Hôpitaux Universitaires de Strasbourg (HUS)
- Agroécologie [Dijon] ; Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté [COMUE] (UBFC)
- Hôpital Henri Mondor ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Service d'immunologie clinique [Créteil] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Service d'hépatologie médicale [CHU Cochin] ; Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Physiopathologie du système immunitaire (Inserm U1223) ; Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Université Paris Descartes - Paris 5 (UPD5)
- Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- French National Agency for Research on Aids and Viral Hepatitis(ANRS) with the participation of Glaxo-SmithKline, Roche and Schering-Plough.
- ANRS CO13-HEPAVIH Study Group
Description
BACKGROUND AND AIMS:Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use.DESIGN:A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires.SETTING:Data were collected across 17 hospitals in France.PARTICIPANTS:All HIV-HCV co-infected patients who initiated HCV treatment during follow-up and answered items regarding substance use in at least one yearly questionnaire (258 patients, 671 visits).INTERVENTION:HCV treatment consisted of Peg-IFN-based regimens.MEASUREMENTS:Four time-varying outcomes: hazardous alcohol use (Alcohol Use Disorders Identification Test-C > 3/4 for women/men), number of alcohol units/month, binge drinking, cannabis and tobacco use. Mixed models assessed the effect of HCV treatment status (not yet treated, treated and HCV-cleared, treated and HCV-chronic) on each outcome.FINDINGS:A significant decrease (more than 60% reduction) in both hazardous alcohol use and binge drinking and a reduction of 10 alcohol units/month was observed after HCV treatment (irrespective of HCV clearance). No significant effect of HCV treatment status was found on tobacco use and regular cannabis use, but HCV 'clearers' reported less non-regular use of cannabis.CONCLUSIONS:Hepatitis C virus (HCV) treatment appears to help HIV-HCV co-infected patients reduce alcohol use.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://www.hal.inserm.fr/inserm-01982433
- URN
- urn:oai:HAL:inserm-01982433v1
Origin repository
- Origin repository
- UNICA